Oramed Pharmaceuticals, Inc. engages in the provision of oral delivery solutions for drugs delivered via injection. The company is headquartered in New York City, New York and currently employs 13 full-time employees. The company went IPO on 2002-04-01. The firm has developed an oral dosage form intended to withstand the harsh environment of the stomach and effectively deliver active biological insulin or other proteins. Its Protein Oral Delivery (POD) technology is designed to protect drug integrity and increase absorption. Its pipeline includes ORMD-0801 (Oral Insulin) Diabetes, ORMD-0801 (Oral Insulin) NASH, and ORMD 0901 (Oral GLP-1). Its oral insulin (ORMD-0801) has the potential to create a new paradigm in the treatment of diabetes through oral delivery of insulin at an earlier stage of treatment. Its oral insulin capsule (ORMD-0801) has shown a reduction of liver fat content in early clinical trials. The company is also developing an oral Glucagon-like peptide-1 (GLP-1) analog capsule (ORMD-0901), which is an incretin hormone that stimulates the secretion of insulin from the pancreas.
Mr. Nadav Kidron es el Chairman of the Board de Oramed Pharmaceuticals Inc, se unió a la empresa desde 2006.
¿Qué tal es el rendimiento del precio de la acción ORMP?
El precio actual de ORMP es de $3.42, ha disminuido un 0% en el último día de negociación.
¿Cuáles son los temas de negocio principales o las industrias de Oramed Pharmaceuticals Inc?
Oramed Pharmaceuticals Inc pertenece a la industria Pharmaceuticals y el sector es Health Care
¿Cuál es la capitalización bursátil de Oramed Pharmaceuticals Inc?
La capitalización bursátil actual de Oramed Pharmaceuticals Inc es $136.1M
¿Es Oramed Pharmaceuticals Inc una compra, una venta o una posición de mantener?
Según los analistas de Wall Street, 3 analistas han realizado calificaciones de análisis para Oramed Pharmaceuticals Inc, incluyendo 0 fuerte compra, 0 compra, 3 mantener, 1 venta, y 0 fuerte venta
